The FDA has approved Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Drug overdose deaths in the United States decreased from an estimated 110,037 in 2023 to 80,391 in 2024. HealthDay News — Drug overdose deaths decreased by 26.9 percent from 2023 to 2024, according to ...

HealthDay News — Preinjury mobility data predicts recovery following a lower-extremity fracture in adults, according to a proof-of-concept study published online April 28 in the Journal of Bone & ...

Gabapentinoids are not associated with risk for self-harm in adults; however, elevated risk is seen before initiation of treatment, during the initial phase of treatment, and after discontinuation of ...